Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8344214 | Molecular Genetics and Metabolism | 2011 | 5 Pages |
Abstract
Therapeutic demands in infants and young children with PD need to be tailored according to the patient presentation, and underlying cardiac and fluid-volume status. Desensitization allowed both patients to continue alglucosidase alfa treatment at the recommended dose without prolonged interruption of therapy, or further reactions.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Biochemistry
Authors
Areeg H. El-Gharbawy, Joanne Mackey, Stephanie DeArmey, Greg Westby, Sherry G. Grinnell, Peggy Malovrh, Robert Conway, Priya S. Kishnani,